Low-density lipoprotein lowering therapy: an analysis of the options.
作者： Frank M Sacks
DOI: 10.1016/S0735-1097(02)02609-8
关键词:
摘要: The hydromethylglutaryl coenzyme A (HMG CoA) reductase inhibitors, “statins,” have been remarkably effective in reducing low-density lipoprotein (LDL) cholesterol concentration, decreasing the incidence of coronary heart disease (CHD) and stroke, extending survival [(1–5)][1]. Statins
elsevier.com
onlinejacc.org 参考文章(38)
D. B. Hunninghake, M. E. Stepanavage, M. R. Melino, C. A. Dujovne, H. G. Schrott, E. A. Stein, D. Kush, W. Insull, S. Campodónico, I. D. Escobar, R. S. Scott, A. C. Tate, M. Wu, M. Mercuri, Y. B. Mitchel, S. R. Weiss, M. Bertolami, L. Ose, H. Bays, J. J P Kastelein, M. H. Davidson, Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutrition Metabolism and Cardiovascular Diseases. ,vol. 10, pp. 253- 262 ,(2000)
Salim Yusuf, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary The Lancet. ,vol. 360, pp. 7- 22 ,(2002)
Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up The Lancet. ,vol. 359, pp. 1379- 1387 ,(2002) , 10.1016/S0140-6736(02)08351-4
Terje R. Pedersen, Lars Wilhelmsen, Ole Færgeman, Timo E. Strandberg, Gudmundur Thorgeirsson, Linda Troedsson, Johan Kristianson, Kåre Berg, Thomas J. Cook, Torben Haghfelt, John Kjekshus, Tatu Miettinen, Anders G. Olsson, Kalevi Pyörälä, Hans Wedel, Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering American Journal of Cardiology. ,vol. 86, pp. 257- 262 ,(2000) , 10.1016/S0002-9149(00)00910-3
Terry A. Jacobson, “The Lower the Better” in Hypercholesterolemia Therapy: A Reliable Clinical Guideline? Annals of Internal Medicine. ,vol. 133, pp. 549- 554 ,(2000) , 10.7326/0003-4819-133-7-200010030-00015
F. Ezzet, D. Wexler, P. Statkevich, T. Kosoglou, J. Patrick, L. Lipka, L. Mellars, E. Veltri, V. Batra, The plasma concentration and LDL-C relationship in patients receiving ezetimibe. The Journal of Clinical Pharmacology. ,vol. 41, pp. 943- 949 ,(2001) , 10.1177/00912700122010915
Christopher P. Cannon, Carolyn H. McCabe, Rene Belder, Jeanne Breen, Eugene Braunwald, Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology. ,vol. 89, pp. 860- 861 ,(2002) , 10.1016/S0002-9149(02)02201-4
Gordon Schectman, Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment Annals of Internal Medicine. ,vol. 125, pp. 990- 1000 ,(1996) , 10.7326/0003-4819-125-12-199612150-00011
Donald M. Black, Rebecca G. Bakker-Arkema, James W. Nawrocki, An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor JAMA Internal Medicine. ,vol. 158, pp. 577- 584 ,(1998) , 10.1001/ARCHINTE.158.6.577
Anne Carol Goldberg, Clinical trial experience with extended-release niacin (niaspan): dose-escalation study American Journal of Cardiology. ,vol. 82, pp. 35- ,(1998) , 10.1016/S0002-9149(98)00952-7